Comparative analysis of medications for antibiotic therapy of chronic obstructive pulmonary disease in the pharmaceutical market of Ukraine and France

Authors

DOI:

https://doi.org/10.14739/2409-2932.2020.3.216223

Keywords:

chronic obstructive pulmonary disease, antibiotic therapy, marketing

Abstract

 

The aim of the work – comparative analysis of the assortment of registered medicines for antibiotic therapy of chronic obstructive pulmonary disease (COPD) in the domestic market and similar segment of the French market.

Materials and methods. The study of drug assortment in Ukraine was carried out according to the State Register of Medicines of Ukraine, employing the directory of medicines Compendium online, Anatomical Therapeutic Chemical Classification, web-resource Tabletki.UA. Database Base de données publique des médicaments was consulted while studying the pharmaceutical market in France. The following methods were used: information search, marketing analysis, graphical, comparative and logical methods.

Results. A comparative analysis of medicines employed in Ukraine and France for antibiotic therapy of chronic obstructive pulmonary disease (COPD) was performed.

Conclusions. Pharmaceutical markets of drugs for antibiotic therapy of COPD in Ukraine and France are analyzed. As of January 2020, there are 43 brand names (BN) of medicines with 73 available range items registered in Ukraine, and 87 BN medicines with 150 available range items registered in France. The analysis of drugs assortment showed that foreign drugs predominate in Ukraine and France, their share is 84 % and 55 %, respectively. Among the drug-importing countries, the leaders in Ukraine are India and Germany, and in France they are Spain, England and Germany. The share of domestic drugs in Ukraine and France is lower – 16 % and 45 %, respectively. The leaders among domestic manufacturers in Ukraine are Yuria-Pharm LLC and Astrapharm LLC, in France they are Sanofi Winthrop Industrie, Mylan S.A.S., Delpharm Tours, Delpharm Lille S.A.S. and Panpharma. In the two countries, the majority of drugs for COPD antibiotic therapy treatment is manufactured as powders for solutions and injections, and as tablets; their share in Ukraine is 41 % and 33 %, in France – 19 % and 59 %, respectively. Monocomponent drugs prevail in Ukraine and France. Since the Ukrainian pharmaceutical market, in comparison with the French drug market, is significantly dominated by foreign drugs, it is important to develop new domestic drugs that would be used in COPD treatment.

References

Pertseva, T. O., Hashynova,хроническая обструктивная болезнь легких; антибиотикотерапия; маркетинговые исследования K. Yu., & Yefimova, N. O. (2010). Pokaznyky funktsii endoteliiu u cholovikiv shcho paliat iz khronichnym obstruktyvnym zakhvoriuvanniam leheniv [Indicators of endothelial function in men who smoke with chronic obstructive pulmonary disease]. Medychni perspektyvy, 15(3), 36-40. [in Ukrainian].

Pertseva, T. O. (2015). Khronichne obstruktyvne zakhvoriuvannia lehen mozhlyvosti modyfikatsii perebihu [Chronic obstructive pulmonary disease: the possibility of modifying the course]. Astma ta alerhiia, 4, 55-56. [in Ukrainian].

Mostovyi, Yu. M. (2016). Khronichne obstruktyvne zakhvoriuvannia lehen. Kliuchovi pytannia [Chronic obstructive pulmonary disease. Key issues]. Ukrainskyi medychnyi chasopys, (4), 63-65. [in Ukrainian].

World Health Organization. (2017, December 1). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

Feshchenko, Yu. I. (2015, March 27). HOZL v Ukraine: problemyi i puti resheniya [COPD in Ukraine: problems and solutions]. Health-ua.com. http://health-ua.com/article/15486-hozl-v-ukraine-problemy-i-puti-resheniya

Budniak, L. I., & Dynia, Ye. Yu. (2020). Doslidzhennia asortymentu preparativ dlia likuvannia khronichnoho obstruktyvnoho zakhvoriuvannia lehen na farmatsevtychnomu rynku Ukrainy [Investigation of the assortment of medicines for the treatment of chronic obstructive pulmonary disease in the pharmaceutical market of Ukraine]. Current issues in pharmacy and medicine: science and practice, 13(1), 122-127. [in Ukrainian]. https://doi.org/10.14739/2409-2932.2020.1.198186

(2018). Kompendium. Lekarstvennye preparaty [Compendium. Medicines]. [in Russian]. http://compendium.com.ua

Veshnyaya, S. (2020, February 1). Retsepty aptechnykh prodazhiv. Apteky Frantsii [Recipes for pharmacy sales. Pharmacies in France.]. [in Ukrainian]. https://www.rap.in.ua/apteky-francziyi/

Normatyvno-Dyrektyvni Dokumenty MOZ Ukrainy [Regulatory and legislative documents of the Ministry of Health of Ukraine]. [in Ukrainian]. http://mozdocs.kiev.ua/

Ministry of Solidarity and Health. (2020). Base de données publique des medicaments [Public drug database]. [in France]. http://base-donnees-publique.medicaments.gouv.fr/

Ministry of Health of Ukraine. (n.d.). Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State register of medicines of Ukraine]. [in Ukrainian]. http://www.drlz.kiev.ua

ATC-klassyfykatsyya [ATC-classification]. Kompendium. Lekarstvennye preparaty. [in Ukrainian]. https://compendium.com.ua/atc/

Downloads

How to Cite

1.
Budniak LI, Darzuli NP. Comparative analysis of medications for antibiotic therapy of chronic obstructive pulmonary disease in the pharmaceutical market of Ukraine and France. Current issues in pharmacy and medicine: science and practice [Internet]. 2020Nov.16 [cited 2024Apr.26];13(3). Available from: http://pharmed.zsmu.edu.ua/article/view/216223

Issue

Vol. 13 No. 3 (2020)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)